Antipsychotic Trials in Schizophrenia: The CATIE Project

Antipsychotic Trials in Schizophrenia: The CATIE Project

by T. Scott Stroup
     
 

View All Available Formats & Editions

ISBN-10: 0521895332

ISBN-13: 9780521895330

Pub. Date: 04/01/2010

Publisher: Cambridge University Press

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the

Overview

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

Product Details

ISBN-13:
9780521895330
Publisher:
Cambridge University Press
Publication date:
04/01/2010
Pages:
330
Product dimensions:
6.00(w) x 9.30(h) x 0.80(d)

Table of Contents

List of contributors ix

Acknowledgments xi

Introduction xiii

1 Study design and protocol development process T. Scott Stroup Joseph P. McEvoy Jeffrey A. Lieberman 1

2 Statistical considerations Sonia M. Davis Gary G. Koch Robert A. Rosenheck Vicki G. Davis 22

3 Effectiveness and efficacy: staying on treatment and symptom reduction Joseph P. McEvoy T. Scott Stroup Jeffrey A. Lieberman 39

4 Cost-effectiveness and cost-benefit analysis Robert A. Rosenheck Douglas L. Leslie 57

5 Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study Marvin S. Swartz 80

6 Neurocognition Richard S. E. Keefe 97

7 Vocational outcomes Sandra G. Resnick Robert A. Rosenheck 120

8 Family outcomes Deborah A. Perlick Richard Kaczynski Robert A. Rosenheck 133

9 Extrapyramidal side effects Stanley N. Caroff Del D. Miller Robert A. Rosenheck 156

10 Metabolic side effects and risk of cardiovascular disease Jonathan M. Meyer Donald C. Goff Joseph P. McEvoy 173

11 Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome Fred Reimherr Marvin S. Swartz John L. Olsen 189

12 Violence in schizophrenia: prevalence, correlates, and treatment effectiveness Jeffrey Swanson Richard Van Dorn 207

13 Genetic investigations in the Catie sample James J. Crowley Patrick F. Sullivan 237

14 Human subjects considerations T. Scott Stroup Paul Appelbaum 255

15 Population pharmacokinetics of antipsychotics Kristin L. Bigos Robert R. Bies Stephen R. Marder Bruce G. Pollock 267

16 Implications for research design and study implementation T. Scott Stroup Jeffrey A. Lieberman 281

17 Conclusion and implications for practice and policy Robert A. Rosenheck T. Scott Stroup Jeffrey A. Lieberman 288

Index 307

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >